Companies › Seismic Therapeutic AU
2 active drug programs in 3 registered trials: 3 Phase 1; Other, Immunology; next expected readout Sep 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| S-4321 IRAK4 inhibitor (innate immune modulator) | – | Phase 1 | Healthy Volunteer; Autoimmune Diseases | Sep 2027 |
| S-1117 | – | Phase 1 | Healthy Volunteer | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06828393 | S-1117 | Phase 1 | Healthy Volunteer | Other | Mar 2026 |
| NCT06877611 | S-4321 | Phase 1 | Healthy Volunteer | Other | Apr 2026 |
| NCT07455578 | S-4321 | Phase 1 | Autoimmune Diseases | Immunology | Sep 2027 |
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.